Inflectra/CT-P13* (infliximab) is an approved‡§ biosimilar infliximab.1
Demonstrated comparable efficacy and safety profile to Remicade®† in rigorous clinical studies for RA and AS.1-3
Via extrapolation, Inflectra is licensed for all of the same therapeutic indications as Remicade®.§,1-3
CT-P13* has more than 370,000 patients years of exposure across indications.4
Infliximab is a cornerstone treatment for many inflammatory diseases – with more than 15 years of clinical experience across all indications.5-12
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021